NRSN Live signals | Maximize Profits with Getagraph.com

SELL 132388 min ago

@ $1.320

Issued: 14 Feb 2024 @ 12:31

Return: -9.85%

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 11:54):

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases...

Stats
Today's Volume	12 040.00
Average Volume	289 650
Market Cap	20.63M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.190 ) 2024-05-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.0180 (1.51%)

Volume Correlation

Long: -0.13 (neutral)

Short: -0.29 (neutral)

Signal:(50.882) Neutral

NeuroSense Therapeutics Correlation

10 Most Positive Correlations
TARA	0.944
BNIXU	0.931
CREX	0.931
VSMV	0.925
KYMR	0.924
UNCY	0.921
NICE	0.919
KNSL	0.917
MRUS	0.913
LECO	0.913

10 Most Negative Correlations
DSWL	-0.892
CRCT	-0.892
RTPY	-0.885
OSTK	-0.882
BLKB	-0.881
SGML	-0.878
SRNGW	-0.878
DPRO	-0.875
BIOL	-0.872
BSGM	-0.871

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuroSense Therapeutics Correlation - Currency/Commodity

0.19
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.39
( neutral )

NeuroSense Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2023
Revenue:	$0
Gross Profit:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2022
Revenue:	$0
Gross Profit:	$-89 000.00 (0.00 %)
EPS:	$-0.970

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

NeuroSense Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.